Quality-of-life effects of prostate-specific antigen screening.

• After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Aged

Diagnostic Errors

adverse effects

Early Detection of Cancer

adverse effects

psychology

Europe

Follow-Up Studies

Humans

Male

Mass Screening

Middle Aged

Prostate-Specific Antigen

blood

Prostatic Neoplasms

blood

diagnosis

mortality

Quality of Life

Quality-Adjusted Life Years

Randomized Controlled Trials as Topic

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)